Rheumatology Medical News about juvenile idiopathic arthritis;etanercept

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis
Arthritis & Rheumatism, 08/31/09

Giannini EH et al. – Etanercept or etanercept plus MTX has an acceptable safety and effectiveness profile in children with selected categories of JIA. Improvement was maintained for 3 y in those continuing to receive medication.

Methods

2-18 y old RF+ or RF- patients with polyarthritis, systemic JIA, or extended oligoarthritis were enrolled
Patients received MTX (≥ 10 mg/m2/w), etanercept (0.8 mg/kg/w), or etanercept + MTX for 3 y in an open-label, non-randomized study

Results

197, 103, and 294 patients were enrolled in the MTX, etanercept, and etanercept + MTX groups, respectively
The rates of AEs were 4.6, 7.1, and 6.0 per 100 patient-years, respectively
Medically important infections were similar (1.3, 1.8, and 2.8 per 100 patient-years, respectively)
Scores for physician's global assessment and total active joints improved from baseline, and improvement was maintained for the duration of the study

<< Previous
Decline in rheumatoid vasculitis prevalence among US veterans: A...

Next >>
Ultrasound lung comets in systemic sclerosis: a chest sonography...